Sygnature Discovery
The drug discovery and preclinical services provider made two appointments, with Dr. Allan Jordan and Louisa Jordison joining the organization to support the company’s growth trajectory.
Jordan has been named director of oncology drug discovery and will build Sygnature’s oncology drug discovery capabilities and cellular biology. For the past decade, he had been working at Cancer Research UK.
In a newly-created position, Jordison will help lead the company’s planning, growth and capital projects as the director of strategic planning. She has held roles at Experian, Deloitte, and KPMG.
Sygnature Discovery CEO Dr. Simon Hirst said: "Louisa’s and Allan’s appointments mark a further step in the development of Sygnature as a leading player in the global drug discovery and pre-clinical CRO sector. They demonstrate our commitment to sustainable and secure growth of our company and continuing to broaden and enrich our in-house capabilities and therapeutic area expertise so that we are in an optimal position to serve our growing customer base."
